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Introduction
Non-small cell lung carcinoma (NSCLC) accounts for 85% of all cases
of lung cancer, which is increasingly a disease of older patients [1]. More
than two thirds of NSCLC cases are diagnosed in persons of age 65 years
or older and one in three patients is aged 75 years or older [2]. Data from
the Surveillance, Epidemiology, and End Results (SEER) registry indicate
that the median age at diagnosis of NSCLC patients is 69 years [3].
NSCLC can therefore be regarded as a disease of the elderly and the pro-
portion of the elderly among NSCLC patients is expected to progressively
increase due to the aging of the populations in many countries [4]. Aging
is inextricably associated with physiological changes as they relate to func-
tional status, organ function, and drug pharmacokinetics.
Aging is associated with decreases in marrow reserve, drug clearance
and lean body mass. Furthermore, concomitant co-morbidities that affect
functional status, general health and tumor symptoms are frequently pres-
ent in this patient population [5]. Age itself is not a negative predictive
factor and NSCLC treatment should not be omitted solely on the basis of
chronological age [6]. It is functional impairment and comorbidity, not
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Purpose
As the number of elderly patients diagnosed with non-small cell lung carcinoma (NSCLC) in-
creases, the number of these patients receiving chemotherapy also increases. However, limited
data exists regarding the use of chemotherapy in advanced NSCLC patients who are 75 years of
age or older.
Materials and Methods
Between May 2002 and October 2008, data for 48 advanced NSCLC patients who were 75 years
of age or older who had been treated with chemotherapy were retrospectively analyzed.
Results
The median age of study participants at the time of first line chemotherapy was 76 years (range,
75 to 87 years) and their median Charlson comorbidity index was 2 (range, 1 to 4). Of the total 48
patients, 43 patients (90%) were treated by platinum-based doublet as a first line chemotherapy
regimen. Median progression free survival for first line chemotherapy was 5.7 months (95% con-
fidence interval [CI], 4.93 to 6.47 months) with an overall response rate of 33.3%. After first line
chemotherapy, only 14 of the 48 patients (29.2%) received second line chemotherapy. The median
overall survival (OS) for these patients was 8.2 months (95% CI, 4.44 to 11.96 months). Multivariate
analysis results indicated that female gender and having received second-line or more
chemotherapy were independent prognostic factors for increased OS for all 48 patients. Charlson
Index was not a significant independent prognostic factor for survival. There were 9 treatment
related deaths due to infectious causes (18.8%).
Conclusion
Patients 75 years of age or older with advanced NSCLC may obtain clinical benefit from the ad-
ministration of platinum-based doublet or single agent chemotherapy. However, oncologists must
consider the aspect of safety in relation to the clinical benefits when managing this patient group.
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학회지(44-1)_in  12. 3. 27.  오후 2:23  페이지 37chronological age, that effect treatment tolerance and effectiveness in
NSCLC cases [7].
Most elderly patients are diagnosed with an already advanced stage
disease and the majority of those diagnosed with earlier stage disease will
ultimately suffer disease progression [7]. Systemic chemotherapy has been
a mainstay of therapy for patients with recurrent or advanced NSCLC.
Several meta-analyses of randomized clinical trials have demonstrated
that platinum-based combination chemotherapy induced a modest but
significant survival advantage over best supportive care alone in patients
with untreated, recurrent, or advanced NSCLC. However, platinum-based
doublets are often unsuitable for elderly patients due to the existence of
deficits in patient functional status and organ function. Oncologists have
several treatment options for elderly patients with advanced NSCLC, in-
cluding  best  supportive  care  without  chemotherapy,  single  agent
chemotherapy with a third generation drug, non-platinum-based combi-
nation chemotherapy, platinum-based combination chemotherapy, and
new biologic agents. There has been limited available chemotherapy data
for elderly patients with advanced NSCLC [8]. Elderly patients are ex-
cluded from participation in many clinical trials and often receive untested
or inadequate treatment based on the long held, yet completely unsub-
stantiated, notion that cancer in the elderly is less aggressive and older pa-
tients are incapable of tolerating the exigencies of treatment [9]. Although
the importance of more active treatment for elderly NSCLC patients is
increasingly being recognized, the interactions between age, performance
status and comorbidity, remain uncertain.
In this study, we analyzed the details of chemotherapy regimens and
outcomes for NSCLC patients older than 75 years of age, a demographic
group known to account for more than 30% of newly diagnosed NSCLC
cases. In addition, we investigated performance status (PS) and comor-
bidity burden as a prognostic factor in those patients.
M ater ials  and  Methods
1. Patients
We retrospectively reviewed the records of 48 advanced NSCLC pa-
tients who were 75 years of age or older and who had been treated with
systemic chemotherapy as a first line therapy at the Korea University
Anam Hospital (Seoul, Korea) between May 2002 and October 2008. All
patients had pathologically or cytologically proven advanced/metastatic
or recurrent NSCLC. Clinicopathological information including gender,
age at diagnosis, smoking history, and the type of chemotherapy were re-
trieved from the patients’ electronic medical history records. We catego-
rized patient comorbidity-burden according to the Charlson index [10,11].
The Charlson index provided a weighted index of comorbidity based on
relative risks of death associated with 19 clinical conditions. We set cutoffs
of Charlson index 0 to 1 as “mild,” Charlson index 2 to 3 as “moderate,”
and Charlson index 4 or greater as “severe” comorbidities. This study was
approved by the institutional review board at the Korea University Anam
Hospital.
2. Chemotherapy
The chemotherapy regimen to be used was determined by the treating
physician but the decision to administer first line chemotherapy depended,
in all cases, on patient acceptance. Chemotherapy was repeated every 2-3
weeks according to the regimen. After every 2 or 3 chemotherapy cycles,
tumor measurements were prepared using chest computed tomography
scan and other tests used to stage the tumor. Responses were classified
according to the Response Evaluation Criteria in Solid Tumors (RECIST)
1.0. Toxicity was graded according to the National Cancer Institute com-
mon toxicity criteria (NCI-CTC) version 3.0. The severity of any toxicities
not defined in NCI-CTC were graded as 1=mild, 2=moderate, 3=severe
or 4=very severe.
3. Statistical analysis
Treatment outcomes were estimated as response rate, disease control
rate, overall survival (OS) and progression free survival (PFS). Tumor re-
sponse was determined according to RECIST 1.0. The efficacy analysis
was based on the intent-to-treat population. OS was defined as the time
between the date of recurrent or metastatic disease diagnosis and the date
of death from any cause. PFS was defined as the time between the date
of the recurrent or metastatic disease diagnosis to the date of disease pro-
gression or death from any cause. The Kaplan-Meier method was em-
ployed to estimate the probability of survival and survival difference was
analyzed by the log-rank test. The two-sided significance level was set at
p＜0.05. Cox proportional hazards regression model was employed in
univariate and multivariate analyses to identify the significant independent
prognostic factors of various clinical parameters for survival. Significant
prognostic variables in the univariate analysis for OS were included in the
multivariate analysis. p-value less than 0.05 was considered statistically
significant.
Results
1. Patient characteristics
Of the 117 NSCLC patients 75 years of age or older, 48 were advanced
NSCLC patients treated with systemic chemotherapy as a first line ther-
apy. The clinical characteristics of these patients are shown Table 1. The
median age of the patients was 76 years (range, 75 to 87 years) and the
male/female ratio was 3.4/1.0. The median Eastern Cooperative Oncology
Group (ECOG) PS was 1 (range, 0 to 2), and 11 patients (23%) had never
smoked. At the time of diagnosis with NSCLC, 6 patients had diabetes
mellitus and 11 patients were being treated for hypertension. The majority
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of patients had moderate comorbid disease with 2 patients having severe
comorbid disease (Charlson index≥4). Twenty-nine of 48 patients
(60.5%) had the histologic subtype of lung adenocarcinoma and all pa-
tients had advanced metastatic or recurrent disease.
2. Chemotherapy
As the first line of chemotherapy, 43 of 48 patients (90%) received plat-
inum-based combination chemotherapy. For platinum-based doublet, the
relative dose intensity was 83.2% and the median number of treatment
cycles was four (range, 1 to 6 cycles). The chemotherapeutic agent added
to platinum was gemcitabine in 28 patients, taxane in 10 patients, irinote-
can in 4 patients and pemetrexed in 1 patient. Front line single agent
chemotherapy including vinorelbine, gemcitabine and docetaxel, was ad-
ministered to 5 patients (Table 2). Of the 48 patients receiving first line
chemotherapy, 1 complete response and 15 partial responses were ob-
served (overall response rate, 33.3%). Stable disease was observed in 18
patients (37.5%) and the disease control rate was 70.8%. Of the 48 patients
with first line chemotherapy, progressive disease was observed in 5 pa-
tients (10.4%), and 14 patients (29.2%) received second line chemother-
apy. The regimens used as second line therapy included epidermal growth
factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in 6 patients,
docetaxel in 4 patients, pemetrexed in 2 patients, and vinorelbine in 2 pa-
tients. There was no significant difference for OS results associated with
second line chemotherapy regimens (p＞0.005). Also, there was no sig-
nificant difference in OS results between patients with or without EGFR-
TKI as second or more line of therapy (p＞0.005).
Table 2. Treatment summary of elderly patients with advanced NSCLC
Characteristics No. (%) (n=48) 
First line chemotherapy regimen VNR/GEM/DTX 1/2/2 (2/4/4)
Platinum-based doublet 43 (90)
Post-first line chemotherapy regimen  Second line 14 (29.2)
Third line 6 (12.5)
Fourth line 3 (6.3)
Fifth line 1 (2)
Response to first line chemotherapy  CR 1 (2)
PR 15 (31.2)
SD 18 (37.5)
PD 5 (10.4)
Not evaluable 9 (18.8)
Efficacy of first line chemotherapy  Overall response rates 33.3%
Disease control rates 70.8%
NSCLC, non-small cell lung carcinoma; VNR, vinorelbine; GEM, gemcitabine; DTX, docetaxel; CR, complete remission; PR, partial remission;
SD, stable disease; PD, progressive disease.
Table 1. Baseline characteristics of elderly patients with advanced
NSCLC
Characteristics
No. (%) 
(n=48)
Median age (range, yr) 76 (75-87)
75-80 36 (75)
≥ 80 12 (25)
Gender Male 37 (77)
Female 11 (23)
Performance status ECOG 0 4 (8.3)
ECOG 1 33 (68.8)
ECOG 2-4 1 (22.9)
Smoking status Never smoker 11 (23)
Current smoker or ever smoked 37 (77)
Hypertension Yes 11 (23)
No 37 (77)
Diabetes Yes 6 (12.5)
No 42 (87.5)
Charlson Index 0-1 10 (20.8)
2-3 36 (75)
≥ 4 2 (4.2)
Histology Adenocarcinoma 29 (60.5)
Non-adenocarcinoma 19 (39.5)
Stage IIIB 5 (10.4)
IV 42 (87.6)
Recurrent 1 (2)
No. of  0 5 (10.4)
metastasized regions 1 19 (39.6)
2 18 (37.5)
3 6 (12.5)
NSCLC, non-small cell lung carcinoma; ECOG, Eastern Cooper-
ative Oncology Group.
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3. Survival and prognostic factors
All 48 patients were included in the survival analysis on an intent-to-
treat basis. The median follow up duration was 9.7 months. Median PFS
for first line chemotherapy was 5.7 months (95% confidence interval [CI],
4.93 to 6.47 months) (Fig. 1) and the median OS was 8.2 months (95%
CI, 4.44 to 11.96 months) (Fig. 2). Univariate analysis revealed that de-
creased OS was significantly associated with male-gender, no-response
for first line chemotherapy, and having not received a second line or more
of chemotherapy (Table 3). From the multivariate analysis results, male-
gender (hazard ratio [HR], 0.338; 95% CI, 0.141 to 0.808%; p=0.015)
and not having received a second line or more of chemotherapy (HR,
0.357; 95% CI, 0.171 to 0.745%; p=0.006) were significantly associated
with decreased OS (Table 3). Age (75-80 years vs. ≥ 80 years), ECOG
PS (0-1 vs. 2-4) and Charlson index (mild comorbidity vs. moderate/se-
vere comorbidity) were not significant independent prognostic factors for
survival.
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Fig. 1. Progression free survival (PFS) in first line chemotherapy. CI,
confidence interval.
Fig. 2. Overall survival (OS). PFS, progression free survival, CI, con-
fidence interval.
Table 3. Prognostic factors for overall survival in multivariate analysis
Overall survival
Variables Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Age (75-80 yr vs. ≥ 80 yr) 0.947 (0.489-1.833) 0.872
Gender (male vs. female ) 0.432 (0.205-0.912) 0.028 0.338 (0.141-0.808) 0.015
ECOG PS (0-1 vs. 2-4) 0.562 (0.281-1.121) 0.102
Smoking status (yes vs. no) 0.518 (0.250-1.073) 0.077
Hypertension (yes vs. no) 1.125 (0.554-2.283) 0.744
DM (yes vs. no) 0.827 (0.348-1.965) 0.668
Charlson index (0-1 vs. 2-4 and ≥ 4) 0.609 (0.289-1.282) 0.192
Histology (AD vs. non-AD) 0.737 (0.394-1.381) 0.341
Number of metastasized region (0-1 vs. 2-3) 1.248 (0.696-2.239) 0.458
Efficacy for first line CTx (responders vs. non-responders) 0.428 (0.225-0.816) 0.010 0.688 (0.337-1.408) 0.306
Post-first line chemotherapy (yes vs. no) 0.467 (0.246-0.888) 0.020 0.357 (0.171-0.745) 0.006
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; DM, diabetes mellitus; AD, ade-
nocarcinoma; CTx, chemotherapy.
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4. Toxicities and the causes of death
Toxicities observed during the treatments are listed in Table 4. NCI-
CTC grade 3 or 4 hematologic toxicities included leukopenia in 26 patient,
thrombocytopenia in 9 patients and anemia in 5 patients. Six patients ex-
perienced febrile neutropenia. Grade 3 or 4 non-hematologic toxicities
included diarrhea, mucositis, peripheral neuropathy and anaphylaxis. The
death of 47 patients was observed as revealed in Table 5. The majority of
patients (76.6%) died due to the progression of NSCLC. One patient died
of a cardiovascular event and another due to the progression of an under-
lying usual interstitial pneumonia, instead of NSCLC.
Discussion
Treatment of elderly patients presenting comorbidity with NSCLC is
a serious challenge for clinicians. Generally, the elderly are excluded from
participation in clinical trials and are undertreated, or they receive therapies
that have not been tested in relevant clinical trials [12]. A systematic review
of the recruitment barriers for elderly patients to clinical trials revealed
exclusions related to trial design (e.g., protocol eligibility criteria with re-
strictions on age, comorbid conditions, or organ function requirements
necessary to optimize treatment tolerability) and individual physician
skepticism (e.g., the perception that the patient would not be able to tolerate
treatment due to comorbidities and advanced age) [13]. However, several
age specific subgroup analyses of phase III trials have failed to demon-
strate differences in response rate, PFS and OS between age groups
[14,15]. Little information is available regarding the management of ad-
vanced NSCLC in patients 75 years of age or older. In this study, median
PFS for first line chemotherapy was 5.7 months (95% CI, 4.93 to 6.47
months) with an overall response rate of 33.3%. The median OS was 8.2
months (95% CI, 4.44 to 11.96 months). These outcomes were consistent
with previous studies which were meta-analyses for first line chemother-
apy in advanced or metastatic NSCLC [16,17]. Studies included in the
meta-analyses were intended for patients in their 50s and 60s [16,17]. This
finding implies that chronological age does not impact NSCLC treatment
effectiveness. In this study, only 29.2% of patients received a second line
of chemotherapy and only 6 received EGFR-TKIs as a line of treatment,
due to limitations of the Korean medical insurance system. These factors
may influence the relatively lower OS result observed.
Age is not a negative predictive factor and treatment should be not
omitted on the basis of chronological age alone [6]. Oncologists increas-
ingly recognize and accept the need for more aggressive treatment of eld-
erly NSCLC patients. However, toxicity is an important factor influencing
treatment decisions. Two retrospective pooled analyses reported similar
time to progression and OS between older and younger patients, however,
significantly higher toxic side-effects were reported for the older patients
[18]. Nakamura et al., also revealed no differences in the response or sur-
vival rates between age groups (< 70 years vs. ≥ 70 years) [19]. The most
frequent toxicity, neutropenia, tended to be more common in the older
patients. In this study, grade 3 or greater neutropenia was observed in
54.2% of cases and febrile neutropenia in 12.5%, a frequency comparable
to that of other studies that were meta-analyses of platinum-based
chemotherapy used in first line treatment of advanced NSCLC [16,17].
However, in this study, 9 patients died of infectious causes during first
line chemotherapy. All of those patients had received cisplatin-based
chemotherapy. These findings suggest that cisplatin-based chemotherapy
may not be appropriate alone but could be used with platinum at doses
attenuated to elderly NSCLC patients. Until now, the safety and efficacy
of platinum-based combination chemotherapy in elderly patients with ad-
vanced NSCLC has not been confirmed. Although advanced age alone
does not prelude combination therapies, given the increased likelihood of
comorbidities, age should still be taken into consideration when selecting
an appropriate regimen and dose in a clinical setting. However, there has
been no data establishing appropriate chemotherapy regimens for elderly
patients with advanced NSCLC.
Single agent chemotherapy has been considered the standard treatment
for elderly NSCLC patients. A phase III multicenter trial demonstrated
that single agent vinorelbine improved quality of life and survival com-
pared with supportive care alone [20]. Several trials showed that the plat-
inum-doublet may be more beneficial for elderly NSCLC patients than
single agent chemotherapy [21]. Recently, Davidoff et al. [22], reported
a)UIP, usual interstitial pneumonia.
Toxicity type
Toxicity 
Grade 3 Grade 4
Hematologic toxicity
Leukopenia 19 7
Thrombocytopenia  8  1
Anemia  5  
Febrile neutropenia  4  2
Non-hematologic toxicity
Diarrhea  7
Mucositis  11  1
Peripheral neuropathy  2
Anaphylaxis  1
Table 5. Causes of death
No. (n=47) %
Pneumonia 7 14.9
Bacteria 4
Not identified pathogen 3
Sepsis (bacteria) 2 4.2
Progression of lung cancer 36 76.6
Cardiovascular events 1 2.1
Othera) 1 2.1
Table 4. Treatment-related worst grade of toxicity during first line
chemotherapy
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that, in clinical practice, two thirds of NSCLC patients with chemotherapy
received a platinum-doublet first line regimen. In our results, 43 of 48 pa-
tients (90%) received a platinum-doublet first-line chemotherapy. Plat-
inum-based chemotherapy is currently recommended as the standard
approach for patients with advanced NSCLC [23,24]. However, to date,
no prospective phase III trial that has explored the reproducibility of this
benefit in elderly patients has been published. Due to association with sig-
nificant organ toxicities, a rigorous risk versus benefit evaluation should
be performed, particularly for elderly patients, before choosing cisplatin
administration as an alternative to doublet.
C onclusion
This study had limitations including a small number of patients all com-
ing from a single institution, and a heterogeneous patient group. Never-
theless, this study results suggest that advanced NSCLC patients, 75 years
of age or older, may receive clinical benefit from platinum-based doublet
or single agent chemotherapy. However, oncologists must consider the
safety aspect as well as the clinical benefit when managing this patient
group. The two important lessons from our study are: first, platinum-dou-
blet chemotherapy could be effective for elderly patients with advanced
NSCLC, and secondly, patient selection is important and a strategy should
be explored to avoid fetal toxicity in this age group. Further specifically
designed randomized phase III trials for elderly NSCLC patients are
needed to evaluate the standard treatment against the various options
which include targeted agent, single agent, non-platinum-doublet and plat-
inum-doublet.
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